Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
Volume 1.41M
Average 1.73M
LRMR EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Larimar Therapeutics, Inc.NASDAQ: LRMR
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.35, compared with -$0.46 a year earlier. Trailing-twelve-month EPS (Basic) was -$2.1.
Context
- EPS (Basic) grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 6 analysts of -$1.66 (+26.8%) for the fiscal year ending Dec 2026, a step up from the -72.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.35+52.1% QoQ
- Last fiscal yearDec 2025
- -$2.27-72.0% YoY
- LTMMar 2026
- -$2.1-40.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.9% | +3.4% | -20.5 pp |
| 1 year | -72.0% | +26.8% | +98.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (2.27) USD
- Year-over-year change
- -72.0%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.27) | -72.0% |
| FY2024 | 2024-12-31 | (1.32) | -57.1% |
| FY2023 | 2023-12-31 | (0.84) | +36.8% |
| FY2022 | 2022-12-31 | (1.33) | +54.6% |
| FY2021 | 2021-12-31 | (2.93) | — |
EPS (Basic) vs competitors
How LRMR compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of -40.9% is the 9th highest of 11, against a peer median of -4.9%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -CHF 0.66 CHF | -32.0% | — | |
| LTM Mar 2026 | -$0.93 USD | +26.2% | — | |
| LTM Mar 2026 | -$1.22 USD | -3.4% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | -$1.32 USD | -109.5% | — |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$1.45 USD | +56.1% | — |
| LTM Mar 2026 | -$1.62 USD | +62.1% | — | |
| LTM Mar 2026 | -$1.93 USD | -63.6% | — | |
| LTM Mar 2026 | -$2.1 USD | -40.9% | — | |
| LTM Mar 2026 | -$2.48 USD | -6.4% | — | |
| LTM Mar 2026 | -$3.28 USD | +2.7% | — | |
| LTM Mar 2026 | -$11.68 USD | -23.7% | — | |
| Peer median (excluding LRMR) | — | -4.9% | — | |
Competitors are the stored peer set for LRMR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.4M | 24.25M | 27.67M | 73.28M | 154.22M |
| Selling, General & Admin | 12.07M | 12.28M | 14.09M | 17.61M | 18.27M |
| Operating Expenses | 50.47M | 36.53M | 41.76M | 90.89M | 172.5M |
| Depreciation & Amortization | 326K | 318K | 311K | 318K | 350K |
| EBITDA | (50.31M) | (35.04M) | (36.64M) | (80.29M) | (165.32M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (50.47M) | (36.53M) | (41.76M) | (90.89M) | (172.5M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (171K) | 1.17M | 4.81M | 10.29M | 6.82M |
| Income Before Tax | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (50.64M) | (35.36M) | (36.95M) | (80.6M) | (165.67M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| EPS (Diluted) | (2.93) | (1.33) | (0.84) | (1.32) | (2.27) |
| Weighted Avg Shares | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
| Weighted Avg Shares (Diluted) | 17.16M | 25.76M | 43.9M | 61.26M | 72.95M |
Larimar Therapeutics, Inc.
NASDAQ:LRMR
Intrinsic Alpha fair value
Locked
Current Price
$3.23
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.